轻度至中度COVID-19患者肺表面活性剂的变化
Spela Kokelj1, Per Larsson1, Emilia Viklund1
1Occupational and Environmental Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
PloS one
|August 7, 2025
概括
轻度的COVID-19会改变气道表面活性脂,影响恒温. 脂质谱中的这些变化即使在呼吸系统疾病恢复后也会持续下去.
科学领域:
- 肺部医学 肺部医学
- 生物化学 生物化学
- 病毒学 病毒学
背景情况:
- 在严重的COVID-19中注意到肺表面活性剂的变化,但对轻度至中度病例的数据有限.
- 这项研究调查了轻度至中度COVID-19患者的小呼吸道中的蛋白质和脂配置文件.
研究的目的:
- 探索患有轻度至中度COVID-19的患者小气道中的蛋白质和脂样本.
- 评估基线和恢复后这些概况的变化.
主要方法:
- 使用呼出空气中的颗粒 (PExA) 方法收集呼吸道内液体.
- 采用SOMAscan进行蛋白质分析和液体染色学与双重质谱学 (LC-MS/MS) 进行脂分析.
- 包括29例COVID-19病例和17例健康对照,22例病例在康复后进行了随访.
主要成果:
- 分析显示了95种脂类和46种蛋白质. 在基线13种脂质物种和随访24种脂质物种中,在病例和对照之间观察到显著的差异.
- 在康复后的COVID-19病例中,酸乙烯胺 (PE) 类明显较低.
- 虽然蛋白质配置文件显示没有显著差异,但20种脂质物种从基线变化到随访.
结论:
- 呼吸道内液 (RTLF) 中表面活性物脂的变化表明,在轻度至中度的COVID-19中表面活性物恒温受到影响.
- 这些观察到的脂变化随着时间的推移而持续,表明对表面活性剂平衡的长期影响.
相关概念视频
Breathing
60.3K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
60.3K
COPD: Pathogenesis and Clinical Features
525
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
525
COPD: Management Using Bronchodilators and Corticosteroids
312
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
312
Acute Respiratory Failure-V
208
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
208
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K


